# Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)

> **NCT05733572** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Benedetto Falsini** · enrollment: 36 (estimated)

## Conditions studied

- Optic Pathway Glioma

## Interventions

- **DRUG:** CHF6467
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05733572
- **Lead sponsor:** Benedetto Falsini
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733572, "Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05733572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*